




#DHC16 | @NYeHealth

mHealth Diagnostics



Milovan Stankov-Pugès,
Co-founder & CEO
NG Biotech





About NG Biotech



Privately owned



4 years of service



2 patents



20 FTE

R&D - Manufacturing



21 CFR compliancy (2017)



Founded by Rapid Test Industry Pioneers

Mission

*Leverage Healthcare value with a new generation of « **multiplex** », « **quantitative** » and « **connected** » point of care diagnostics*





Rapid, Mobile, Connected Diagnostics



NG-Test[®] Platform

(Patented)

Blood
Urine
Saliva



Quantitative
Multiplex

NG-Test[®] Reader

(Patent pending)



Patient & doctor centered
diagnostic solutions



hCG testing in ER



US Emergency Rooms



*>9.5 M hCG tests performed in US ER
13% of total women visits (CDC, 2011)*

Laboratory results



*Too long waiting time
40min to 2h*

Rapid urine test



*Urine collection delay
Accuracy - False negatives*



Ideal solution



Publication **The Journal of Emergency Medicine**

SUBSTITUTING WHOLE BLOOD FOR URINE IN A BEDSIDE PREGNANCY TEST

Christian Fromm, MD, Department of Emergency Medicine, Maimonides Medical
Center, 4802 Tenth Avenue,
Brooklyn, NY 11209

The Journal of Emergency Medicine, Vol. 43, No. 3, pp. 478–482, 2012



No waiting for lab results

No urine sample collection



Developed solution



Each pouch includes all components to perform the test

Sensitivity	Clinically Validated
10 mIU/ml	Yes (~400 women) >99% sensitivity & specificity

Qualitative rapid test

Marketed in EU (CE marked)



Results in 5 minutes

Decision making without delays

Higher throughput & cost effective

Quantitative rapid test

Ongoing development (Q1 2017)



0 to 500 000 mIU/ml (without dilution)

Ideal for monitoring
(miscarriage, termination of pregnancy)



Focus on user-friendliness



Blood Precision hCG

World's first fully-integrated blood-based rapid test





Ongoing mHealth developments



Ovarian stimulation

Problematic : Numerous phlebotomies, waiting time to get results, 2 different locations for ultra sound and biological analysis

Solution : Estradiol, LH, Progesterone and hCG quantitative tests

Advantages : Simplify ovarian stimulation follow up, optimize the therapy readjustment with higher analysis frequency, decrease cycle cancelation rates, improve patient comfort, reduce costs



Antibiotic Resistance

Problematic : In the United States, >2M people become infected with bacteria that are resistant to antibiotics; at least 23,000 people die each year (CDC)

Solution : Range of beta lactamase rapid tests
(CTX-M-15, OXA-48, KPC-1, NDM-1, IMP-1, VIM-1 / VIM-2 and MCR-1)

Advantages : Screening simplicity, multiplex and rapidity (post culture growth results in 4 hours)



Zika

Problematic: Zika outbreak, no rapid tests available, dangerous for pregnant women (microcephaly)

Solution : Multiplex Zika, Chikungunya, Dengue Yellow fever rapid test

Advantages : Multiplex, Rapidity, Simplicity



US market strategy



Partner to evaluate, register & market NGB products in the US

Partner to develop new mHealth diagnostics

2nd fund raising round open to US investors (\$5M)

Open an office in the US in 2017

